Active Biotech

“The potential of this type of treatment is vast. There is definitively an unmet need for effective, local delivery of therapeutic agents. Here we have a big advantage, we know that already at 1-3 times per day you see a very nice dose-dependent type of availability of laquinimod in the posterior parts of the eye. The next step would be to show therapeutic efficacy in patients,” said Principal Investigator and Professor of ophthalmology, Dr. Quan Dong Nguyen.

The interview with Principal Investigator and Professor of ophthalmology, Dr. Quan Dong Nguyen, and co-Investigator Dr. El Feky from the Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, was conducted after a presentation by Dr. El Feky on June 27, and is available here. In the recorded interview, Active Biotech’s Chief Medical Officer Dr. Erik Vahtola also presents the background of laquinimod and details regarding the study design, patient population and study results. Dr. El Feky’s presentation is available here.

The results provide a strong rationale to initiate a phase II/III clinical program in patients with uveitis where there is a high unmet medical need for a non-steroidal treatment option. Active Biotech’s focus for the laquinimod program is now directed towards identifying the best development partner for the continued clinical development of laquinimod in eye disorders. Active Biotech has previously communicated the positive topline results from the LION study.